Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Larimar Therapeutics, Inc. (NASDAQ: LRMR) resulting from allegations that Larimar Therapeutics may have issued materially misleading business information to the investing public.
If you purchased Larimar Therapeutics securities and would like to join the prospective action, please click “Join This Class Action.”
On September 29, 2025, Investing.com published an article entitled “Larimar stock falls as anaphylaxis events overshadow positive frataxin data.” The article stated that Larimar “stock faced pressure following the disclosure of seven anaphylaxis events that occurred in the open-label study of nomlabofusp for Friedreich’s ataxia (FA).”
On this news, Larimar stock fell 33.66% on September 29, 2025.
The Rosen Law Firm has been ranked among the top 4 law firms each year since 2013 for the number of successful securities class actions on behalf of investors. In 2019 alone, our firm recovered $438 million for investors.
Investors should carefully identify and select experienced counsel with a track record of success leading securities class actions. Often other firms issue press releases about class actions yet do not have comparable experience or resources.
Institutional Shareholders Services ranked the Rosen Law Firm # 1 for the number of securities class action recoveries in 2017.
The Rosen Law Firm represents investors throughout the globe. Our mission is to prosecute securities fraud class actions and protect shareholders’ rights.
